(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 March 2005 (17.03.2005)

PCT

(10) International Publication Number
WO 2005/023261 A1

(51) International Patent Classification[7]: A61K 31/496, 31/495, C07D 295/18, A61P 25/28

(21) International Application Number: PCT/EP2004/009699

(22) International Filing Date: 31 August 2004 (31.08.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
03019682.8 9 September 2003 (09.09.2003) EP

(71) Applicant *(for all designated States except US)*: **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, CH-4070 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **ALBERATI-GIANI, Daniela** [IT/CH]; Kirchplatz 4, CH-4800 Zofingen (CH). **JOLIDON, Synese** [CH/CH]; Stutzhalde 2, CH-4223 Blauen (CH). **NARQUIZIAN, Robert** [FR/FR]; 4, Rue de Montreux, F-68300 St. Louis (FR). **NETTEKOVEN, Matthias, Heinrich** [DE/DE]; Winkelmatten 9, 79639 Grenzach-Wyhlen (DE). **NORCROSS, Roger, David** [GB/CH]; Alte Saline 20, CH-4310 Rheinfelden (CH). **PINARD, Emmanuel** [FR/FR]; 7, rue de Pujo, F-68480 Linsdorf (FR). **STALDER, Henri** [CH/CH]; St. Johanns-Ring 145, CH-4056 Basel (CH).

(74) Agent: **POPPE, Regina**; Grenzacherstrasse 124, CH-4070 Basel (CH).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: 1-BENZOYL-PIPERAZINE DERIVATIVES AS GLYCINE UPTAKE INHIBITORS FOR THE TREATMENT OF PSYCHOSES



(I)

(57) Abstract: The invention relates to compounds of formula (I) wherein Ar is substituted aryl or unsubstituted or substituted 6-membered heteroaryl, containing one, two or three nitrogen atoms, and wherein the aryl and the heteroaryl groups may be substituted by one or more substituents selected from the group consisting of hydroxy, halogen, CN, (C_1C_6)-alkyl, (C_1-C_6)-alkyl substituted by halogen, (C_1-C_6)-alkoxy, (C_1-C_6)-alkoxy substituted by halogen, NR^7R^8, $C(O)R^9$ or SO_2R^{10}; R^1 is hydrogen or (C_1-C_6)-alkyl; R^2 is halogen, (C_1-C_6) -alkyl, (C_2-C_6) -alkenyl, wherein a hydrogen atom may be replaced by CN, $C(O)$-R^9 or (C_1-C_6)-alkyl, or is (C_2-C_6)alkynyl, (C_1-C_6)-alkyl substituted by halogen, -$(CH_2)_n$-(C_3-C_7)-cycloalkyl, -$(CH_2)_n$-heterocycloalkyl, -$C(O)$-R^9, -$(CH_2)_n$-aryl or -$(CH_2)_n$-5 or -6membered heteroaryl containing one, two or three heteroatoms, selected from the group consisting of oxygen, sulphur or nitrogen wherein aryl, cycloalkyl, heterocycloalkyl and heteroaryl are unsubstituted or substituted by one or more substituents selected from the group consisting of hydroxy, halogen, (C_1-C_6)-alkyl, (C_1-C_6)-alkyl substituted by halogen or (C_1-C_6) alkoxy; R^3, R^4 and R^6 independently from each other are hydrogen, hydroxy, halogen, (C_1-C_6)-alkyl or (C_1-C_6)-alkoxy; R^5 is NO_2, CN, $C(O)R^9$, SO_2R^{10} or $NR^{11}R^{12}$; R^7 and R^8 independently from each other are hydrogen or (C_1-C_6)-alkyl; the other substituents are defined in the claims; and to pharmaceutically acceptable acid addition salts thereof for the treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.

WO 2005/023261 A1